A Study of Subcutaneous Versus Intravenous MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in Patients With Previously Untreated CD20-Positive Diffuse Large B-Cell Lymphoma

NCT01649856 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

572

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG: CHOP
DRUG: rituximab [MabThera/Rituxan]
DRUG: rituximab [MabThera/Rituxan]

Sponsor

Hoffmann-La Roche